Capacity Is Not Security: The Missing Capability Behind Pharmaceutical Self-Reliance
A factory is visible. Dependence is often invisible. For decades, industrial policy has tended to measure strength through things that can easily be counted: factories established, investment committed, machines installed, tonnes of capacity created and jobs announced. Pharmaceuticals expose the weakness of this approach more clearly than most industries. A plant may exist on paper and machinery may be ready to operate, yet the country can remain vulnerable if the plant cannot obtain critical inputs, maintain quality, control costs, retain skilled people and sell its output competitively. Capacity tells us what might be produced. Security depends on what can be produced reliably when it is actually needed.
India’s pharmaceutical success created a new kind of vulnerability. The rise of the Indian pharmaceutical industry is one of the important industrial stories of the post-1970 period. Process chemistry capabilities, generic medicines, entrepreneurial manufacturing and a large domestic market helped India become an important global supplier. But success in finished formulations did not automatically create independence across the entire production chain. Over time, economics encouraged firms to source some bulk drugs, key starting materials and intermediates from highly competitive external suppliers. This was commercially rational for individual companies. At the level of the national economy, however, concentrated dependence created strategic risk. The lesson is uncomfortable but important: an industry can become globally successful at one stage of a value chain while simultaneously becoming vulnerable at another.
The new policy response is therefore necessary, but capacity should not be confused with the outcome. A Department of Pharmaceuticals release dated 27 March 2026 reported that 38 projects had been commissioned under the bulk-drug PLI scheme by December 2025, creating around 56,800 tonnes of annual capacity. It also highlighted support under PRIP for pharmaceutical research and stronger industry–academia linkages. These are meaningful programme milestones. But commissioned capacity does not tell us how much is being produced continuously, whether production is cost competitive, whether buyers are shifting from imports, whether plants can withstand price cycles, or whether strategically critical dependencies have actually fallen.
Tonnes may be the wrong unit for measuring security. Fifty thousand tonnes of relatively replaceable material may matter less strategically than a few hundred tonnes of an input without which an essential medicine cannot be manufactured. The future pharmaceutical-security map therefore cannot simply count aggregate domestic production. It must identify critical molecules, intermediates and starting materials; the number and geographical concentration of suppliers; switching possibilities; lead times; inventory requirements; quality constraints; and the consequences of disruption. Supply-chain security is ultimately about the importance of the missing component, not its weight.
The harder challenge begins after the factory is built. Pharmaceutical manufacturing is unforgiving. A producer must manage chemistry, process yields, energy, solvents, effluent treatment, analytical testing, equipment maintenance, documentation, regulatory compliance, working capital and customer qualification simultaneously. Failure in one area can undermine investment in all the others. This is particularly important for MSMEs. Smaller pharmaceutical companies may not need another subsidy as much as they need access to a process engineer, faster analytical testing, dependable utilities, affordable environmental services, regulatory expertise or patient working capital.
This is where cluster policy needs to change from building common facilities to solving common production problems. Before creating another testing centre, laboratory or common infrastructure facility, institutions should ask what is actually stopping enterprises from producing reliably. Is testing taking too long? Are specialised engineers unavailable? Is effluent treatment expensive? Are firms struggling with validation or documentation? Are utilities unreliable? Is process development weak? A shared facility without a clearly identified production bottleneck can become another building searching for users. The better cluster institution begins with the problem and only then decides whether the solution requires infrastructure, skills, technology, finance or coordination.
Biotechnology makes this distinction even sharper. Laboratories, incubators and research grants are useful, but buildings do not automatically produce innovation. Biotech capability develops when clearly defined technical problems meet capable scientific teams, patient capital, specialised equipment, intellectual-property strategy, regulatory pathways and firms capable of commercialisation. The distance between an experiment and a commercially viable product can be enormous. India therefore needs to measure not simply research expenditure or laboratories created, but how effectively knowledge moves from university to experiment, from experiment to validation, from validation to manufacturing and finally from manufacturing to the market.
The next stage of self-reliance must therefore be less dramatic and more demanding. The first generation of industrial policy asked whether India could manufacture something domestically. The next generation must ask whether India can manufacture it continuously, competitively and at the required quality without permanent protection. That means measuring plant utilisation, batch consistency, rejection rates, yields, delivery reliability, import displacement at the level of critical inputs, customer retention and the ability to survive normal movements in international prices.
Procurement and incentives can help companies cross the difficult early years. Strategic reserves may be justified for exceptionally critical materials. Public support can also help create markets where initial economics are difficult. But an industry that survives only while extraordinary support continues has created subsidised capacity rather than genuine resilience.
By the 2030s, pharmaceutical security may increasingly become a capability race rather than a capacity race. Countries will compete through process efficiency, advanced chemistry, biologics, continuous manufacturing, AI-assisted drug discovery, automation, regulatory credibility, traceable supply chains and the ability to move discoveries rapidly into commercial production. In such a world, simply possessing factories will become progressively less meaningful.
The real test of Atmanirbhar pharmaceutical manufacturing should therefore be surprisingly simple: Can the system keep supplying when conditions become difficult?
If production remains consistent, quality remains trusted, critical inputs remain available, customers continue buying and firms remain commercially viable, capacity has become capability.
That is when industrial capacity becomes industrial security.
#Pharma #Biotech #MSMEs #AtmanirbharBharat #SupplyChainResilience #Manufacturing #IndustrialPolicy



